Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy

NCT ID: NCT02404818

Last Updated: 2022-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-04-30

Study Completion Date

2021-04-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate if radiation and chemotherapy treatment cause cardiac abnormalities among survivors of Hodgkin's lymphoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin's Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Survivors of Hodgkin's lymphoma

Cardiac Magnetic Resonance Imaging and Echocardiogram

Cardiac Magnetic Resonance Imaging

Intervention Type PROCEDURE

A cardiac MRI will be performed.

Echocardiogram

Intervention Type PROCEDURE

An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac Magnetic Resonance Imaging

A cardiac MRI will be performed.

Intervention Type PROCEDURE

Echocardiogram

An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Completed radiation and chemotherapy treatment for Hodgkin lymphoma involving the mediastinum.
* Patient must be ≥ 18 years at time of consent.

Exclusion Criteria

* Pregnant women at time of Cardiac MRI
* Contraindications to Cardiac MRI (contrast allergy, metal implants, medical devices)
* Glomerular filtration rate (GFR) \< 30, unless approved by Radiologist (UF Health Jacksonville Radiology Policy: Administration of Gadolinium-Based Contrast Agents).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bradford S Hoppe, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

University of Florida Health Proton Therapy Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida Health Proton Therapy Institute

Jacksonville, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB201703302

Identifier Type: OTHER

Identifier Source: secondary_id

UFPTI-1431-HL02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Home Hospital for Lymphoma
NCT04423848 TERMINATED NA